Exact claim · Version 1 · Reviewed 2026-07-23
“Cardiovascular trial results prove a universal longevity benefit.”
A verdict on this wording and scope, not a universal grade for Liraglutide.
01 · Verdict
Not established
LEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults with type 2 diabetes and high cardiovascular risk in LEADER.
- Category
- Longevity
02 · Primary record
Check the attached evidence
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.